Surrozen (SRZN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $23.44, -6.50% vs the prior close of $25.07.
- Volume 268.99K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SRZN slides 6.5% to $23.44. Closed at $23.44, -6.50% vs the prior close of $25.07. Day range $23.28–$25.09, opened at $25.01.
SRZN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SRZN slides 6.5% to $23.44
- Closed at $23.44, -6.50% vs the prior close of $25.07. Day range $23.28–$25.09, opened at $25.01.
- Volume was 268.99K shares, 0.4x its 50-day average of 599.43K — lighter than usual.
- Price is -1.3% vs its 50-day average ($23.74) and -5.3% vs its 200-day average ($24.74).
- 52-week range $11.39–$37.83; today's close sits at 46% of that range, 38.0% below the 52-week high.
Oct 15, 2026 — SRZN jumps 5.6% to $25.07
- Closed at $25.07, +5.56% vs the prior close of $23.75. Day range $23.31–$25.32, opened at $23.73.
- Volume was 363.80K shares, 0.6x its 50-day average of 598.82K.
- Price is +5.7% vs its 50-day average ($23.71) and +1.4% vs its 200-day average ($24.73).
- 52-week range $11.39–$37.83; today's close sits at 52% of that range, 33.7% below the 52-week high.
Oct 14, 2026 — SRZN rises 1.0% to $23.75
- Closed at $23.75, +1.02% vs the prior close of $23.51. Day range $22.67–$24.54, opened at $23.40.
- Volume was 631.50K shares, 1.1x its 50-day average of 591.69K.
- Price is +0.4% vs its 50-day average ($23.64) and -3.9% vs its 200-day average ($24.71).
- 52-week range $11.39–$37.83; today's close sits at 47% of that range, 37.2% below the 52-week high.
Oct 13, 2026 — SRZN slides 5.0% to $23.51
- Closed at $23.51, -5.05% vs the prior close of $24.76. Day range $21.85–$24.37, opened at $24.04.
- Volume was 868.70K shares, 1.5x its 50-day average of 578.93K.
- Price is -0.4% vs its 50-day average ($23.61) and -4.8% vs its 200-day average ($24.71).
- 52-week range $11.39–$37.83; today's close sits at 46% of that range, 37.9% below the 52-week high.
Oct 12, 2026 — SRZN slides 16.6% to $24.76 on 2.8x normal volume
- Closed at $24.76, -16.60% vs the prior close of $29.69. Day range $22.82–$30.08, opened at $28.70.
- Volume was 1.53M shares, 2.8x its 50-day average of 554.44K — unusually heavy trading.
- Price is +5.0% vs its 50-day average ($23.58) and +0.2% vs its 200-day average ($24.70).
- 52-week range $11.39–$37.83; today's close sits at 51% of that range, 34.5% below the 52-week high.
Oct 9, 2026 — SRZN jumps 6.1% to $29.69
- Closed at $29.69, +6.15% vs the prior close of $27.97. Day range $27.53–$30.97, opened at $27.86.
- Volume was 781.30K shares, 1.4x its 50-day average of 560.26K.
- Price is +26.2% vs its 50-day average ($23.52) and +20.2% vs its 200-day average ($24.69).
- 52-week range $11.39–$37.83; today's close sits at 69% of that range, 21.5% below the 52-week high.
Oct 8, 2026 — SRZN jumps 11.2% to $27.97
- Closed at $27.97, +11.23% vs the prior close of $25.15. Day range $23.54–$28.85, opened at $25.00.
- Volume was 682.20K shares, 1.2x its 50-day average of 552.89K.
- Price is +19.8% vs its 50-day average ($23.35) and +13.4% vs its 200-day average ($24.66).
- 52-week range $11.39–$37.83; today's close sits at 63% of that range, 26.1% below the 52-week high.
Oct 7, 2026 — SRZN slides 4.6% to $25.15, 5 down days in a row
- Closed at $25.15, -4.65% vs the prior close of $26.37. Day range $25.08–$26.21, opened at $25.81.
- Volume was 374.20K shares, 0.7x its 50-day average of 554.59K.
- Price is +8.5% vs its 50-day average ($23.17) and +2.1% vs its 200-day average ($24.63).
- 52-week range $11.39–$37.83; today's close sits at 52% of that range, 33.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — SRZN slides 9.5% to $26.37, 4 down days in a row
- Closed at $26.37, -9.47% vs the prior close of $29.13. Day range $26.18–$29.26, opened at $29.26.
- Volume was 603.80K shares, 1.1x its 50-day average of 545.38K.
- Price is +14.4% vs its 50-day average ($23.06) and +7.1% vs its 200-day average ($24.61).
- 52-week range $11.39–$37.83; today's close sits at 57% of that range, 30.3% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — SRZN dips 0.6% to $29.13, 3 down days in a row
- Closed at $29.13, -0.65% vs the prior close of $29.32. Day range $26.97–$29.70, opened at $29.32.
- Volume was 439.20K shares, 0.8x its 50-day average of 540.28K.
- Price is +27.1% vs its 50-day average ($22.93) and +18.5% vs its 200-day average ($24.58).
- 52-week range $11.39–$37.83; today's close sits at 67% of that range, 23.0% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — SRZN dips 2.3% to $29.32
- Closed at $29.32, -2.27% vs the prior close of $30.00. Day range $28.93–$30.68, opened at $30.57.
- Volume was 646.00K shares, 1.2x its 50-day average of 528.68K.
- Price is +28.9% vs its 50-day average ($22.74) and +19.4% vs its 200-day average ($24.55).
- 52-week range $11.39–$37.83; today's close sits at 68% of that range, 22.5% below the 52-week high.
- SEC filings that day: 8-K.
SRZN latest news & SEC filings
Every SEC filing by or about SRZN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 1, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form 25-NSE — Notice that a security is being removed from exchange listing
Notice that a security is being removed from exchange listing
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $5.00M (prior year $983.00K) (+408.6% vs Jun 30, 2025)
- Net income: $50.18M (prior year $39.75M) (+26.2% vs Jun 30, 2025)
- Diluted EPS: -$0.41 (prior year $2.55) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 24, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Yu Chen-Ming sold 162,500 shares at $21.25 (≈$3.45M) on Jul 22, 2026
- Yu Chen-Ming sold 162,500 shares at $21.25 (≈$3.45M) on Jul 22, 2026
- Yu Chen-Ming sold 162,500 shares at $21.25 (≈$3.45M) on Jul 22, 2026
- Yu Chen-Ming sold 162,500 shares at $21.25 (≈$3.45M) on Jul 22, 2026
- Tcg Crossover Gp Iii, Llc sold 162,500 shares at $21.25 (≈$3.45M) on Jul 22, 2026
- Tcg Crossover Gp Iii, Llc sold 162,500 shares at $21.25 (≈$3.45M) on Jul 22, 2026
- …plus 19 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade SRZN
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 23, 2026, Nov 7, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 11.01% (largest 108.4%). That is a volatile stock.
- Liquidity: about 1.20M shares (≈$28.18M) trade per day on average.
- 52-week position: $23.44 vs a range of $11.39–$37.83 (46% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Chen-Ming Yu sold 162,500 shares on Jul 22, 2026.
- Latest filings: 8-K Oct 2, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 11.75M shares outstanding (Aug 4, 2026), +37.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SRZN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 25.01 | 25.09 | 23.28 | 23.44 | 268.99K |
| Oct 15, 2026 | 23.73 | 25.32 | 23.31 | 25.07 | 363.80K |
| Oct 14, 2026 | 23.40 | 24.54 | 22.67 | 23.75 | 631.50K |
| Oct 13, 2026 | 24.04 | 24.37 | 21.85 | 23.51 | 868.70K |
| Oct 12, 2026 | 28.70 | 30.08 | 22.82 | 24.76 | 1.53M |
| Oct 9, 2026 | 27.86 | 30.97 | 27.53 | 29.69 | 781.30K |
| Oct 8, 2026 | 25.00 | 28.85 | 23.54 | 27.97 | 682.20K |
| Oct 7, 2026 | 25.81 | 26.21 | 25.08 | 25.15 | 374.20K |
| Oct 6, 2026 | 29.26 | 29.26 | 26.18 | 26.37 | 603.80K |
| Oct 5, 2026 | 29.32 | 29.70 | 26.97 | 29.13 | 439.20K |
| Oct 2, 2026 | 30.57 | 30.68 | 28.93 | 29.32 | 646.00K |
| Oct 1, 2026 | 31.60 | 32.00 | 29.72 | 30.00 | 438.40K |
| Sep 30, 2026 | 32.15 | 33.38 | 30.98 | 32.18 | 1.66M |
| Sep 29, 2026 | 29.83 | 32.54 | 29.50 | 31.98 | 558.00K |
| Sep 28, 2026 | 29.71 | 30.39 | 29.01 | 29.64 | 409.70K |
| Sep 25, 2026 | 34.72 | 37.83 | 28.55 | 29.54 | 1.93M |
| Sep 24, 2026 | 30.56 | 35.86 | 29.10 | 33.68 | 11.53M |
| Sep 23, 2026 | 17.54 | 17.54 | 16.14 | 16.16 | 115.50K |
| Sep 22, 2026 | 16.78 | 17.60 | 16.56 | 17.60 | 89.80K |
| Sep 21, 2026 | 16.74 | 17.45 | 16.44 | 16.53 | 129.00K |
About Surrozen
Surrozen (SRZN) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1824893.
SRZN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Eric Bjerkholt | Director | May 14, 2026 |
| Anna Berkenblit | Director | May 14, 2026 |
| Christopher Y Chai | Director | May 14, 2026 |
| Mary Haak-Frendscho | Director | May 14, 2026 |
| Tim Kutzkey | Director | May 19, 2026 |
| Craig C Parker | Chief Executive Officer | Jun 16, 2026 |
| Mace Rothenberg | Director | May 14, 2026 |
| David J Woodhouse | Director | May 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Yang Li | Exec. Vice President, Research | Jun 16, 2026 |
| Andrew Pedrum Maleki | Chief Financial Officer | Jun 16, 2026 |
| Craig C Parker | Chief Executive Officer | Jun 16, 2026 |
| Charles O Williams | Chief Operating Officer | Jun 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 22, 2026 | Chen-Ming Yu | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Chen-Ming Yu | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Chen-Ming Yu | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Chen-Ming Yu | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Iii, Llc Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Iii, Llc Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Iii, Llc Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Iii, Llc Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Fund Ii, L.P. Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Fund Ii, L.P. Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Fund Ii, L.P. Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Fund Ii, L.P. Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Ii, Llc Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Ii, Llc Tcg | Sale | 162,500 | $21.25 |
| Jul 22, 2026 | Crossover Gp Ii, Llc Tcg | Sale | 162,500 | $21.25 |
SRZN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $3.48M | $-242.03M | -32.37 | $-30.24M |
| Dec 31, 2024 | $10.65M | $-63.56M | -21.67 | $-17.63M |
| Dec 31, 2023 | $0 | $-43.04M | -21.33 | $-40.36M |
| Dec 31, 2022 | — | $-36.00M | -15.56 | $-44.15M |
| Dec 31, 2021 | — | $-54.65M | -2.21 | $-48.81M |
Latest balance sheet: total assets $115.61M, total liabilities $334.27M, cash $102.04M (as of Jun 30, 2026).
SRZN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $21.64 |
| May 6, 2026 | 8-K Item 2.02 (results) | $34.13 |
| Mar 23, 2026 | 8-K Item 2.02 (results) | $25.24 |
| Nov 7, 2025 | 8-K Item 2.02 (results) | $12.20 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $9.56 |
| May 9, 2025 | 8-K Item 2.02 (results) | $8.35 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $11.66 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $10.38 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
| Aug 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SRZN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.